-
Ipsos: Total growth of 4.7% and good profitability and cash generation in the first half
来源: Nasdaq GlobeNewswire / 24 7月 2024 10:57:41 America/Chicago
Total growth of 4.7% and good profitability and cash generation in the first half
Total growth: 4.7%
Organic growth: 3.8%
Operating margin: 10.1%
Free cash flow: €80 millionParis, 24 July 2024 – Ipsos, one of the world’s leading market research companies, generated a revenue of €1,138.5 million in the first half of the year, an increase of €51.4 million compared with the first half of 2023.
Revenue (millions of euros) 2024 2023 Total
growthQ1 557.5 532.0 4.8% Q2 581.0 555.1 4.7% Total 1,138.5 1,087.1 4.7% First-half growth stands at 4.7%, including 3.8% organic growth, -1.8% of adverse currency effects, and 2.8% scope effects, linked in particular to the acquisitions of I&O Research in the Netherlands (leader in social and political surveys), Jarmany in the UK (data management and analysis specialist) and B&A in Ireland (expert in opinion and social research studies, as well as market studies), which are achieving good performances a few months after their integration.
Ben Page, CEO of Ipsos, stated: “Ipsos has once again demonstrated the resilience of its operating model, illustrated by organic growth of nearly 4% and a very good level of profitability and cash generation in the first half of the year. Despite a cyclical slowdown linked to elections in many countries (as US, UK, France, India) and specific headwinds in the United States, overall our geographical diversity, the breadth of our range of solutions, our unique expertise and our technological breakthroughs are key fundamentals that enable us to pursue our growth strategy.”
PERFORMANCE BY REGION
In € millions Revenue
2024Contribution Total growth Organic
growthEMEA 523.3 46% 10.0% 7.6% Americas 418.7 37% -0.6% -0.6% Asia-Pacific 196.5 17% 3.4% 4.0% Total 1,138.5 100% 4.7% 3.8% The EMEA region recorded solid organic growth of 7.6% in the first half, driven by Continental Europe and the Middle East. In particular, new management started showing impact in Germany, and with Italy, recorded double-digit growth over the half-year period. The good momentum of recent acquisitions boosted total growth in the region to 10%.
Business in the Americas was down slightly. Latin America maintains a good momentum. In the United States, the solid performance in the consumer goods sector, the very strong performance of our Ipsos Digital platform and the recovery of our activity with major Big Tech clients are confirmed. However, our performance in this region is impacted by the electoral cycle and the end of major one-off contracts which are weighing on our public affairs activities, and by a wave of restructuring by major players in the pharmaceutical industry. In addition to these factors, the US suffered from a lack of management for over 6 months. The recent implementation of a new management organization should allow us to stabilize the situation and to gradually return to growth in North America.
The Asia-Pacific region posted organic growth of 4.0% over the semester. Growth in China remains weak due to a lack of macroeconomic clarity. The rest of the region saw a slowdown in activity during the second quarter, after an excellent first quarter. Some contracts will be finalized later than initially anticipated and should drive activity in the second half of the year, particularly in India.
PERFORMANCE BY AUDIENCE
In € millions 2024
revenueContribution Total growth Organic growth Consumers1 562.3 50% 7.6% 8.0% Clients and employees2 230.3 20% -0.3% 0.5% Citizens3 182.3 16% 10.9% 1.1% Doctors and patients4 163.7 14% -3.1% -2.5% Total 1,138.5 100% 4.7% 3.8% Breakdown of Service Lines by audience segment:
1- Brand Health Tracking, Creative Excellence, Innovation, Ipsos UU, Ipsos MMA, Market Strategy & Understanding, Observer (excl. public sector), Ipsos Synthesio, Strategy3
2- Automotive & Mobility Development, Audience Measurement, Customer Experience, Channel Performance (Mystery Shopping and Shopper), Media Development, ERM, Capabilities
3- Public Affairs, Corporate Reputation
4- Pharma (quantitative and qualitative)Our consumer activities recorded organic growth of 8.0%, reflecting the very good performance in all geographies of our service lines linked to brand health tracking, innovation, advertising creation and our qualitative surveys. Solid performance in the consumer goods sector contributed to this segment’s good performance.
The clients and employees, citizens, and doctors and patients audiences continue to be affected by the difficult environment in the United States. Outside the United States, they posted overall growth of nearly 5%.
New services (platforms, ESG offers, data analytics and advisory) now account for 21.5% of Group revenue. Organic growth was 13%, driven by Ipsos Digital, our DIY solution, which grew by 37% this semester.
FINANCIAL PERFORMANCE
Summary income statement
In € millions 30 June 2024 30 June 2023 Change Reminder
31 Dec. 2023Revenue 1,138.5 1,087.1 4.7% 2,389.8 Gross margin 780.1 736.1 6.0% 1,612.8 Gross margin/Revenue 68.5% 67.7% 67.5% Operating profit 115.1 94.3 22.1% 312.4 Operating profit/Revenue 10.1% 8.7% 13.1% Other non-current/recurring income and expenses 2.4 (0.9) (47.3) Finance costs (5.7) (6.6) (13.3) Other financial income and expenses 2.2 (2.4) (7.0) Income tax (29.0) (20.9) (72.9) Net income (attributable to owners of the parent) 78.0 56.4 38.3% 159.7 Adjusted net income* (attributable to owners of the parent) 82.3 70.1 17.5% 228.6 *Adjusted net profit is calculated before (i) non-monetary items related to IFRS 2 (Share-based Payment), (ii) the amortisation of acquisition-related intangible assets (client relations), (iii) the impact of other non-current income and expenses, net of tax, (iv) the non-monetary impact of changes in puts and other financial income and expenses, and (v) deferred tax liabilities related to goodwill for which amortisation is deductible in some countries.
Income statement items
Gross margin is up 80 basis points to 68.5% compared to 67.7% for last year at this point. This increase in the gross margin ratio is mostly due to (i) the strong growth of Ipsos Digital, whose gross margin rate is significantly higher than the Group average, (ii) the increase in the internalisation of data collection following our investments in our panels.
In terms of operating costs, the payroll rose by 3.3%, compared with a 6% increase in gross margin. This increase reflects a cautious recruitment policy to (i) support our growth, (ii) invest in our technological developments and (iii) strengthen the internalisation of our operations. As at 30 June, the ratio of payroll to gross margin was 68.3%, compared to 70% last year, and remains significantly lower than the pre-pandemic situation (above 72% in 2019).
Overhead costs increased by €8.3 million, mainly due to (i) an increase in IT and technology expenditure reflecting the implementation of our strategic plan and (ii) a perimeter effect linked to the acquisitions of 11 companies since 2023. The ratio of overhead costs to gross margin was 14.9%; like payroll, this ratio remains significantly lower than in 2019 (18.3%).
“Other operating income and expenses”, which mainly consists of severance costs, has a negative balance of €7.7 million, down by €2 million compared to the previous year.
Overall, the operating margin stands at 10.1% for the first half of 2024, an increase of 140 basis points compared to last year.
Net interest expense came to €5.7 million compared with €6.6 million last year, reflecting the fall in the Group’s gross debt between the first half of 2023 and the first half of 2024.
The effective tax rate is 26.0%, compared to 25.8% in the first half of 2023.
Net income attributable to owners of the parent is €78 million, compared to €56 million in the first half of 2023, an increase of 38.3%.
Adjusted net income attributable to owners of the parent is also up at €82 million, compared to €70 million last year, an increase of 17.5%.
Financial structure
Cash flow. Cash flow from operations stands at €177 million, compared to €137 million in the first half of 2023, an increase of €40 million euros, in line with the rise in pre-tax net income.
Working capital requirement improved significantly by €35 million in the first half of 2024 compared with the same period of 2023. As expected, a high level of customer cash collection was recorded in the first half of 2024, in line with the strong level of revenue in the last quarter of 2023.
Investments in property, plant and equipment and intangible assets consist mainly of investments in IT infrastructure and technology and amounted to €32 million in the first half. These investments are up 20%, in line with the implementation of our platforms and technologies roadmap.
Overall, free cash flow from operating activities is €80 million, a €56 million increase compared to last year.
Regarding non-current investments, Ipsos invested over €28 million in the first half of the year, including through the acquisition of Jarmany in the United Kingdom and I&O Research in the Netherlands in January 2024.
Lastly, financing activities for the first half of 2024 include share buybacks in connection with the delivery of free share plans for Group employees.
Equity stood at €1,421 million at 30 June 2024, compared to €1,433 million at 31 December 2023.
Net financial debt amounted to €100 million, down from €120 million at 31 December 2023 and 129 million at 30 June 2023. The leverage ratio (calculated excluding the IFRS 16 impact) was 0.3 times EBITDA (compared to 0.3 times at 31 December 2023 and 0.4 at 30 June 2023).
Cash position. Cash at 30 June 2024 amounted to €283 million, compared to €278 million at 31 December 2023.
The Group has an excellent level of liquidity with nearly €500 million in credit lines maturing in over one year, and no debt maturing in 2024.
OUTLOOK
Thanks to the resilience of its operating model and its strong ability to adapt in challenging macro-economic and geopolitical environments, Ipsos is continuing its growth trajectory and improved its profitability and cash generation in the first half of the year. The Group is in a very good position to continue financing its growth, investments and acquisitions. A few months after their integration, the latest acquisitions achieve a good performance.
In the technological field, the Group is actively pursuing the implementation of its roadmap, both the reboot of its digital data collection engine, and new investments in Artificial Intelligence, by launching new offers based on Ipsos Facto, its own generative AI platform. The Group launched Ipsos PersonaBot, a solution that enables companies to converse with personas representing target consumer segments; and Creative Spark AI, an advertising evaluation solution that predicts human reactions to TV and social videos using a combination of Artificial Intelligence and a large database of real data.
Organic growth in the first half of the year was weaker than expected, particularly at the end of the second quarter. This partly reflects the impact of the electoral cycle and the wait-and-see attitude that result from elections in many countries this year (United States, United Kingdom, France and India notably).
Moreover, the context did not improve in the second quarter in the United States. Once the uncertainties related to the presidential election and the restructuring of the pharmaceutical sector have dissipated, the recent appointment of a new CEO in North America and the implementation of a new management organization should enable a return to growth in this region by the beginning of next year.
In the short term, we are adjusting downwards our organic growth target for 2024 and now anticipate an organic growth close to that of last year (+3%). At the same time, the increase in gross margin and the good cost management discipline allow us to maintain our operating margin target of around 13%.
***
Presentation of half-year results
The 2024 half-year results will be presented on Friday, 25 July 2024 at 8:30 a.m. CET via webcast.
If you would like to register, please contact IpsosCommunications@Ipsos.com.A replay will also be made available on Ipsos.com
Appendices
- Consolidated income statement
- Statement of financial position
- Consolidated cash flow statement
- Statement of changes in consolidated equity
The complete consolidated financial statements as at 31 December 2023 are available on Ipsos.com
ABOUT IPSOS
Ipsos is one of the largest market research companies in the world, present in 90 markets and employing nearly than 20,000 people.
Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.
“Game Changers” – our tagline – summarises our ambition to help our 5,000 clients navigate with confidence our world of rapid change.
Founded in France in 1975, Ipsos has been listed on the Euronext Paris since 1 July 1999. The company is part of the SBF 120, Mid-60 indices, STOXX Europe 600 and is eligible for the Deferred Settlement Service (SRD).
ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP
www.ipsos.com35 rue du Val de Marne
75 628 Paris, Cedex 13 France
Tel. +33 1 41 98 90 00
Notes
Consolidated income statement, Interim financial statements at June 30, 2024In thousands of Euros 30/06/2024 30/06/2023 31/12/2023 Revenue 1,138,537 1,087,127 2,389,810 Direct costs (358,434) (351,004) (777,004) Gross margin 780,104 736,124 1,612,805 Employee benefit expenses – excluding share-based payments (532,663) (515,526) (1,049,836) Employee benefit expenses - share-based payments * (8,253) (8,521) (16,309) General operating expenses (116,404) (108,097) (214,019) Other operating income and expenses (7,699) (9,718) (20,281) Operating margin 115,084 94,262 312,359 Amortization of intangible assets identified on acquisitions * (2,377) (3,173) (5,961) Other non-operating income and expenses* 2,413 (923) (47,293) Share of profit/(loss) of associates (179) (274) (390) Operating profit 114,940 89,892 258,715 Finance costs (5,665) (6,588) (13,284) Other financial income and expenses * 2,187 (2,357) (6,977) Net profit before tax 111,462 80,948 238,454 Income tax – excluding deferred tax on goodwill amortization (29,148) (19,476) (73,089) Deferred tax on goodwill amortization* 168 (1,392) 160 Income tax (28,980) (20,868) (72,929) Net profit 82,482 60,080 165,526 Attributable to the owners of the parent 77,954 56,351 159,725 Attributable to non-controlling interests 4,528 3,729 5,801 Basic net profit per share attributable to the owners of the parent (in euros) 1.81 1.29 3.67 Diluted net profit per share attributable to the owners of the parent (in euros) 1.79 1.26 3.59 Adjusted earnings * 87,616 73,823 234,155 Attributable to the owners of the parent 82,333 70,089 228,584 Attributable to non-controlling interests 5,283 3,734 5,572 Adjusted basic earnings per share, attributable to the owners of the parent 1.91 1.60 5.25 Adjusted diluted earnings per share, attributable to the owners of the parent 1.89 1.57 5.14 * Adjusted for non-cash items related to IFRS 2 (share-based compensation), amortization of intangible assets identified on acquisitions (customer relations), deferred tax liabilities related to goodwill for which amortization is deductible in some countries, the impact net of tax of other non-operating income and expenses and the non-cash impact of changes in puts in other financial income and expenses.
Statement of financial position, Interim financial statements at June 30, 2024
In thousands of Euros 30/06/2024 30/06/2023 31/12/2023 ASSETS Goodwill 1,409,938 1,356,185 1,351,957 Right-of-use assets 106,115 108,995 109,372 Other intangible assets 126,147 110,037 118,127 Property, plant and equipment 30,325 32,765 32,496 Investments in associates 6,273 6,509 6,393 Other non-current financial assets 48,583 55,820 62,592 Deferred tax assets 22,810 6,721 25,431 Non-current assets 1,750,191 1,677,032 1,706,368 Trade receivables 392,361 381,283 561,958 Contract assets 180,835 174,107 129,733 Current tax 21,173 30,601 9,671 Other current assets 71,703 73,500 67,115 Financial derivatives - - - Cash and cash equivalents 282,509 300,781 277,911 Current assets 948,581 960,270 1,046,388 TOTAL ASSETS 2,698,773 2,637,303 2,752,756 in thousands of Euros 30/06/2024 30/06/2023 31/12/2023 EQUITY AND LIABILITIES Share capital 10,801 11,063 10,801 Share paid-in capital 446,174 495,628 446,174 Treasury shares (9,272) (28,468) (965) Translation adjustments (148,283) (148,212) (164,363) Other reserves 1,024,920 972,387 964,926 Net profit attributable to the owners of the parent 77,954 56,351 159,725 Equity, attributable to the owners of the parent 1,402,294 1,358,749 1,416,297 Non-controlling interests 18,607 (248) 16,353 Equity 1,420,901 1,358,501 1,432,650 Borrowings and other non-current financial liabilities 375,518 375,104 374,718 Non-current liabilities on leases 85,738 86,726 87,492 Non-current provisions 5,229 4,506 4,012 Provisions for post-employment benefit obligations 38,870 ,36,065 37,429 Deferred tax liabilities 66,847 70,891 63,283 Other non-current liabilities 51,143 73,560 47,939 Non-current liabilities 623,344 646,851 614,873 Trade payables 282,637 278,976 337,905 Borrowings and other current financial liabilities 7,485 54,497 22,933 Current liabilities on leases 34,970 35,660 37,070 Current tax 31,735 14,054 40,772 Current provisions 4,653 6,224 4,789 Contract liabilities 40,697 42,358 53,916 Other current liabilities 252,349 200,181 207,849 Current liabilities 654,528 631,950 705,233 TOTAL LIABILITIES 2,698,773 2,637,303 2,752,756 Consolidated statement of cash flows, Interim financial statements at June 30, 2024
In thousands of Euros 30/06/2024 30/06/2023 31/12/2023 OPERATING ACTIVITIES - - - NET PROFIT 82,482 60,080 165,526 Items with no impact on cash flow from operations - - - Amortization and depreciation of property, plant and equipment and intangible assets 45,566 43,067 121,703 Net profit of equity-accounted companies, net of dividends received 179 274 390 Losses/(gains) on asset disposals (3,330) 11 147 Net change in provisions 7,676 (1,593) 21,241 Share-based payment expense 7,184 7,336 14,977 Other non-cash income/(expenses) 178 (2,039) (2,816) Acquisition costs of consolidated companies 903 510 1,804 Finance costs 7,462 8,449 16,965 Tax expense 28,980 20,868 72,929 CASH FLOW FROM OPERATIONS BEFORE TAX AND FINANCE COSTS 177,281 136,963 412,865 Change in working capital requirement 7,078 (28,347) (65,246) Income tax paid (49,042) (34,123) (63,441) NET CASH FROM OPERATING ACTIVITIES 135,317 74,493 284,178 INVESTING ACTIVITIES - - - Acquisitions of property, plant and equipment and intangible assets (31,972) (26,533) (58,536) Proceeds from disposals of property, plant and equipment and intangible assets 50 29 75 (Increase)/decrease in financial assets 11,129 (2,270) (3,107) Acquisitions of consolidated activities and companies, net of acquired cash (28,154) (5,467) (46,794) CASH FLOW FROM INVESTING ACTIVITIES (48,947) (34,241) (108,363) FINANCING ACTIVITIES - Share capital increases/(reductions) - - (263) Net (purchases)/ sales of treasury shares (38,682) (63,637) (85,498) Increase in long-term borrowings 49,000 22 70,035 Decrease in long-term borrowings (69,015) (29,635) (127,503) Decrease in long-term loans from associates - - 1,306 Increase/(decrease) in bank overdrafts 208 50 (168) Net repayment of lease liabilities (19,727) (18,471) (37,807) Net interest paid (1,176) (1,684) (12,289) Net interest paid on lease liabilities (1,814) (1,901) (3,719) Acquisitions of non-controlling interests - (622) (1,060) Dividends paid to the owners of the parent - - (58,963) Dividends paid to non-controlling interests in consolidated companies - - (4,092) Dividends received from non-consolidated companies - - - CASH FLOW FROM FINANCING ACTIVITIES (81,206) (115,879) (260,021) NET CHANGE IN CASH AND CASH EQUIVALENTS 5,164 (75,627) (84,206) Impact of foreign exchange rate movements (566) (9,262) (11,522) Depreciation of the Russian cash - - (12,030) CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD 277,911 385,670 385,670 CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 282,509 300,781 277,911 Attachment